4-(4-METHOXYPHENYL)-2-OXO-1-(PHENYLSULFONYL)-6-(THIOPHEN-2-YL)-1,2-DIHYDROPYRIDINE-3-CARBONITRILE


Molecule Category	Free-form
Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	PKMKAIBNFHXCLZ-UHFFFAOYSA-N
Smiles	COc1ccc(cc1)C2=C(C#N)C(=O)N(C(=C2)c3cccs3)S(=O)(=O)c4ccccc4
InChI	InChI=1S/C23H16N2O4S2/c1-29-17-11-9-16(10-12-17)19-14-21(22-8-5-13-30-22)25(23(26)20(19)15-24)31(27,28)18-6-3-2-4-7-18/h2-14H,1H3

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C23H16N2O4S2
Molecular Weight	448.51
AlogP	4.04
Hydrogen Bond Acceptor	5.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	5.0
Polar Surface Area	124.09
Molecular species	NEUTRAL
Aromatic Rings	3.0
Heavy Atoms	31.0

Assay Description	Organism	Bioactivity
Growth inhibition of Homo sapiens (human) NCI-H23 cells at 10 uM after 48 hr by SRB assay	Homo sapiens	20.0 %
Growth inhibition of Homo sapiens (human) RPMI8226 cells at 10 uM after 48 hr by SRB assay	Homo sapiens	22.0 %
Growth inhibition of Homo sapiens (human) MOLT4 cells at 10 uM after 48 hr by SRB assay	Homo sapiens	28.1 %
Growth inhibition of Homo sapiens (human) HL-60(TB) cells at 10 uM after 48 hr by SRB assay	Homo sapiens	55.0 %
Growth inhibition of Homo sapiens (human) CCRF-CEM cells at 10 uM after 48 hr by SRB assay	Homo sapiens	56.2 %
Growth inhibition of Homo sapiens (human) K562 cells at 10 uM after 48 hr by SRB assay	Homo sapiens	27.7 %
Growth inhibition of Homo sapiens (human) HOP92 cells at 10 uM after 48 hr by SRB assay	Homo sapiens	21.3 %

Cross References

Resources	Reference
ChEMBL	CHEMBL2235169
PubChem	45029479

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).